Substance / Medication

Halofantrine

Overview

Active Ingredient
halofantrine
RxNorm CUI
50749

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

12 trials linked to this intervention

12
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base.
Bouchaud Olivier, Imbert Patrick, Touze Jean Etienne et al. · Malar J · 2009
PMID: 20003315Meta-AnalysisFull text (PMC)
Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria.
Klein Kerenaftali, Aarons Leon, Ter Kuile Feiko O et al. · J Pharm Pharmacol · 2012
PMID: 23058047RCT
Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers.
Babalola C P, Kolade Y T, Olaniyi A A et al. · J Clin Pharm Ther · 2009
PMID: 20175801RCT
Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine.
Kolade Yetunde T, Babalola Chinedum P, Olaniyi Ajibola A et al. · Eur J Clin Pharmacol · 2008
PMID: 17952423RCT
Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers.
Omoruyi Sharon I, Onyeji Cyprian O, Daniyan Michael O · Ther Drug Monit · 2007
PMID: 17417075RCT
Comparative determination of halofantrine tablets by titrimetry, spectrophotometry and liquid chromatography.
Kolade Y T, Adegbolagun O M, Idowu O S et al. · Afr J Med Med Sci · 2006
PMID: 17209332Observational
Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice.
Mosqueira Vanessa C F, Loiseau Philippe M, Bories Christian et al. · Antimicrob Agents Chemother · 2004
PMID: 15047523ObservationalFull text (PMC)
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
Porter Christopher J H, Kaukonen Ann Marie, Taillardat-Bertschinger Agnes et al. · J Pharm Sci · 2004
PMID: 15067688Observational
Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula José A, Navarro-Polanco Ricardo A, Sanguinetti Michael C · Naunyn Schmiedebergs Arch Pharmacol · 2004
PMID: 15558243Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Halofantrine (substance)
SNOMED CT
372527008
UMLS CUI
C0120726
RxNorm CUI
50749

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
12
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.